Aventis Lovenox Petition Offers Premarin Defense To Hold Off Generics
Executive Summary
Aventis is trying the Premarin defense in an attempt to hold off generic competition to its antithrombotic agent Lovenox
You may also be interested in...
Aventis Lovenox Promotions Challenged By Coagulation Test Maker
A diagnostics company that developed a coagulation test for use with Lovenox alleges Aventis is falsely promoting the antithrombotic as requiring "no routine monitoring" and being "therapeutic from dose one.
Aventis Lovenox Promotions Challenged By Coagulation Test Maker
A diagnostics company that developed a coagulation test for use with Lovenox alleges Aventis is falsely promoting the antithrombotic as requiring "no routine monitoring" and being "therapeutic from dose one.
Aventis Lovenox Patent Defense: Re-Issuance Higher Priority Than Stay
Aventis' Lovenox generic defense remains centered on the re-issuance of an enoxaparin patent as the company defends the original version against potential generic competition